Valiant Laboratories Limited has informed the Exchange regarding Board meeting held on August 08, 2025 for the Financial Results of quarter ended June 30, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories' board approved audited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) on August 8, 2025, with a clean audit opinion from Raman S. Shah & Co. On a standalone basis, revenue from operations jumped to ₹5,100.73 lakhs from ₹1,888.42 lakhs in Q1 FY25 — a sharp rise of about 170% year-on-year. The company swung from a net loss of ₹100.56 lakhs in Q1 FY25 to a net profit of ₹181.57 lakhs, with EPS of ₹0.42 versus a loss of ₹0.23 earlier. On a consolidated basis (including subsidiary Valiant Advanced Sciences Pvt Ltd), revenue rose to ₹4,682.27 lakhs and net profit came in at ₹182.09 lakhs, again a turnaround from a prior-year loss.
Strong top-line growth and a return to profit signal a major operational turnaround versus the year-ago quarter, which is likely to be viewed positively by shareholders. The clean audit report and absence of exceptional items add further comfort around the numbers.